CLINICAL TRIAL: PXD101 IN RECURRENT OR REFRACTORY CUTANEOUS AND PERIPHERAL T-CEL

临床试验：PXD101 用于治疗复发性或难治性皮肤和外周 T-CEL

• 批准号: 7717898
• 负责人: RAJ ADVANI
• 金额: $ 0.35万
• 依托单位: STANFORD UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-12-01 至 2008-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7717898
• 关键词: Antineoplastic Agents; Clinical Treatment; Clinical Trials; Computer Retrieval of Information on Scientific Projects Database; Cutaneous; Disease; Funding; Grant; In complete remission; Institution; Investigational Drugs; Label; Measures; Multiple Myeloma; Neoplasms; Non-Hodgkin' s Lymphoma; PXD101; Patients; Peripheral; Phase; Phase II Clinical Trials; Prior Therapy; Progressive Disease; Randomized; Rate; Recurrence; Recurrent disease; Refractory; Relapse; Research; Research Personnel; Resources; Safety; Source; Stable Disease; T-Cell Lymphoma; Time; United States National Institutes of Health; Upper arm; design; partial response; response

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is an open-label, non-randomized, multicenter, Phase II trial to assess the efficacy and safety of an investigational drug, PXD101, monotherapy in patients who have failed at least one line of prior therapy. The trial design includes two arms; arm A comprises only patients with recurrent Cutaneous T-cell lymphoma (CTCL), and arm B comprises patients with relapsed or refractory Peripheral T-cell Lymphoma (PTCL) or other T-cell lymphomas. PXD101 is a promising antineoplastic agent for the treatment of hematological neoplasias, and is currently being evaluated in a Phase II clinical trial for the treatment of multiple myeloma. Further clinical trials in patients with Non-Hodgkin's lymphomas (NHL) will delineate the optimal use of PXD101 in these disorders. The primary objective of this trial is to determine the efficacy of PXD101 treatment as measured by response rate (CR=complete response; CRu=CR/unconfirmed; PR=partial response; SD=stable disease; RD=relapsed disease; or PD=progressive disease) using the response criteria of Cheson et al. (Cheson 1999). The secondary objective of the trial is to examine the time to response, the duration of response, and the safety and survival following PXD101 therapy as a single agent.

这个子项目是众多研究子项目之一